Skip to content 
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts. more
| Time Frame | DNA | Sector | S&P500 |
|---|---|---|---|
| 1-Week Return | 10.72% | 0.4% | 0.35% |
| 1-Month Return | -17.99% | -2.57% | -2.66% |
| 3-Month Return | -32.2% | -0.71% | 2.52% |
| 6-Month Return | -44.08% | 11.7% | 18.16% |
| 1-Year Return | -24.46% | 6.84% | 24.83% |
| 3-Year Return | -91.52% | 19.96% | 26.45% |
| 5-Year Return | -91.49% | 71.15% | 88.47% |
| Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
|---|---|---|---|---|---|---|
| Total Revenue | 54.18M | 76.66M | 313.84M | 477.71M | 251.46M | [{"date":"2019-12-31","value":11.34,"profit":true},{"date":"2020-12-31","value":16.05,"profit":true},{"date":"2021-12-31","value":65.7,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":52.64,"profit":true}] |
| Cost of Revenue | - | 15.61M | 129.69M | 204.22M | 108.81M | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":7.64,"profit":true},{"date":"2021-12-31","value":63.51,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":53.28,"profit":true}] |
| Gross Profit | 54.18M | 61.05M | 184.15M | 273.49M | 142.64M | [{"date":"2019-12-31","value":19.81,"profit":true},{"date":"2020-12-31","value":22.32,"profit":true},{"date":"2021-12-31","value":67.33,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":52.16,"profit":true}] |
| Gross Margin | 100.00% | 79.64% | 58.68% | 57.25% | 56.73% | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":79.64,"profit":true},{"date":"2021-12-31","value":58.68,"profit":true},{"date":"2022-12-31","value":57.25,"profit":true},{"date":"2023-12-31","value":56.73,"profit":true}] |
| Operating Expenses | 125.78M | 198.07M | 2.01B | 2.48B | 814.87M | [{"date":"2019-12-31","value":5.07,"profit":true},{"date":"2020-12-31","value":7.98,"profit":true},{"date":"2021-12-31","value":81.07,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":32.83,"profit":true}] |
| Operating Income | (71.60M) | (137.03M) | (1.83B) | (2.21B) | (672.23M) | [{"date":"2019-12-31","value":-7159800000,"profit":false},{"date":"2020-12-31","value":-13702700000,"profit":false},{"date":"2021-12-31","value":-182846700000,"profit":false},{"date":"2022-12-31","value":-220895200000,"profit":false},{"date":"2023-12-31","value":-67223100000,"profit":false}] |
| Total Non-Operating Income/Expense | (44.90M) | 12.39M | (11.19M) | 107.71M | (165.46M) | [{"date":"2019-12-31","value":-41.69,"profit":false},{"date":"2020-12-31","value":11.5,"profit":true},{"date":"2021-12-31","value":-10.39,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-153.62,"profit":false}] |
| Pre-Tax Income | (119.83M) | (124.83M) | (1.84B) | (2.12B) | (892.94M) | [{"date":"2019-12-31","value":-11983500000,"profit":false},{"date":"2020-12-31","value":-12483400000,"profit":false},{"date":"2021-12-31","value":-183812200000,"profit":false},{"date":"2022-12-31","value":-212139900000,"profit":false},{"date":"2023-12-31","value":-89294000000,"profit":false}] |
| Income Taxes | 22.00K | 1.89M | (1.48M) | (15.03M) | (71.00K) | [{"date":"2019-12-31","value":1.16,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-78.35,"profit":false},{"date":"2022-12-31","value":-795.5,"profit":false},{"date":"2023-12-31","value":-3.76,"profit":false}] |
| Income After Taxes | (119.86M) | (126.72M) | (1.84B) | (2.11B) | (892.87M) | [{"date":"2019-12-31","value":-11985700000,"profit":false},{"date":"2020-12-31","value":-12672300000,"profit":false},{"date":"2021-12-31","value":-183664200000,"profit":false},{"date":"2022-12-31","value":-210637200000,"profit":false},{"date":"2023-12-31","value":-89286900000,"profit":false}] |
| Income From Continuous Operations | (119.86M) | (126.72M) | (1.84B) | (2.11B) | (854.25M) | [{"date":"2019-12-31","value":-11985700000,"profit":false},{"date":"2020-12-31","value":-12672300000,"profit":false},{"date":"2021-12-31","value":-183664200000,"profit":false},{"date":"2022-12-31","value":-210637200000,"profit":false},{"date":"2023-12-31","value":-85425300000,"profit":false}] |
| Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
| Net Income | (119.86M) | (126.72M) | (1.84B) | (2.11B) | (892.87M) | [{"date":"2019-12-31","value":-11985700000,"profit":false},{"date":"2020-12-31","value":-12672300000,"profit":false},{"date":"2021-12-31","value":-183664200000,"profit":false},{"date":"2022-12-31","value":-210637200000,"profit":false},{"date":"2023-12-31","value":-89286900000,"profit":false}] |
| EPS (Diluted) | - | - | (1.52) | (1.23) | (0.47) | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":-152,"profit":false},{"date":"2022-12-31","value":-123,"profit":false},{"date":"2023-12-31","value":-47,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
| DNA | |
|---|---|
| Cash Ratio | 5.79 |
| Current Ratio | 6.11 |
| Quick Ratio | 6.11 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
| DNA | |
|---|---|
| ROA (LTM) | -21.82% |
| ROE (LTM) | -63.02% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
| DNA | |
|---|---|
| Debt Ratio Lower is generally better. Negative is bad. | 0.34 |
| Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.66 |
| Debt/Equity The higher the number, the more leverage the business employs, the riskier the investment typically is. | 1.52 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
| DNA | |
|---|---|
| Trailing PE | NM |
| Forward PE | NM |
| P/S (TTM) | 8.65 |
| P/B | 1.98 |
| Price/FCF | NM |
| EV/R | 5.85 |
| EV/Ebitda | NM |
| PEG | NM |
Greenwave Technology Solutions (NASDAQ: GWAV ) stock is rising higher on Tuesday alongside heavy pre-market trading of the metal recycling company’s shares. That has more than 29 million shares of GWAV stock changing hands as of this writing. This is a massive surge in trading volume compared to the company’s daily average of about 4 million shares. It’s worth noting that this heavy trading comes without any recent news from Greenwave Technology Solutions. That includes a lack of press releases or filings with the Securities and Exchange Commission (SEC). There’s also no new analyst coverage that would cause this rally. One thing that is worth noting is GWAV stock’s penny status. That comes from its low prior closing price of just 6 cents and its market capitalization of only $9.801 million. What That Means for GWAV Stock Being in penny stock territory opens GWAV shares up to certain risks. That includes the ability for traders to pump and dump its shares. This is often what’s behind heavy trading of penny stocks when there’s no other news to report.
Cyclacel Pharmaceuticals (NASDAQ: CYCC ) stock is rocketing higher on Tuesday after the clinical-stage biopharmaceutical company withdrew a proposed public offering. A filing with the Securities and Exchange Commission (SEC) has the company withdrawing its proposed public offering filed in March. Cyclacel Pharmaceuticals notes that it won’t be refunded the filing fees but seeks to have them applied to future filings. Here’s a portion of what the company said in its filing with the SEC withdrawing the offering. “The Company has determined not to pursue, at this time, the public offering to which the Registration Statement relates. The Registration Statement has not been declared effective by the Commission and no securities have been issued or sold under the Registration Statement. Accordingly, withdrawal of the Registration Statement is consistent with the public interest and the protection of investors, as contemplated by paragraph (a) of Rule 477.” What This Means for CYCC Stock The withdrawal of this proposed public offering is good news for CYCC stockholders.
Ginkgo Bioworks (NYSE: DNA ) stock has seen a recent surge in short interest combined with a jump in its share price, fueling speculation that a short squeeze is in the makings for DNA stock. Indeed, over the past few days, the number of DNA short shares available has recently sunk from around 750,000 to 0, according to financial data website Fintel . Now, this doesn’t mean that there aren’t any more shore shares available, as Fintel doesn’t sample every single brokerage. But it does show a clear surge in the demand for short shares of DNA stock. Additionally, DNA’s short sale volume has climbed quite dramatically over the past few weeks. In fact, according to the Financial Industry Regulatory Authority (FINRA), the sale of DNA stock has surged to 18.6 million as of last Friday, April 26. This is a steep climb from just weeks ago, when it had a short volume of about 7.3 million on April 16. DNA Stock Surges Amid Short Squeeze Speculation Perhaps most interestingly, however, is that Ginkgo Bioworks stock actually jumped 15% today and is up 17% over the past five trading sessions, even despite the ramping short interest.
IGDI will leverage Ginkgo''s Adaptive Laboratory Evolution technology to improve its sourdough starter culture product PADUA, Italy and BOSTON, April 16, 2024 /PRNewswire/ -- Il Granaio delle Idee (IGDI), an innovative international developer and provider of clean label baking ingredients,…
Ginkgo Bioworks Holdings (DNA) share price today is $0.9266
Yes, Indians can buy shares of Ginkgo Bioworks Holdings (DNA) on Vested. To buy Ginkgo Bioworks Holdings from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in DNA stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Ginkgo Bioworks Holdings (DNA) via the Vested app. You can start investing in Ginkgo Bioworks Holdings (DNA) with a minimum investment of $1.
You can invest in shares of Ginkgo Bioworks Holdings (DNA) via Vested in three simple steps:
The 52-week high price of Ginkgo Bioworks Holdings (DNA) is $2.54. The 52-week low price of Ginkgo Bioworks Holdings (DNA) is $0.74.
The price-to-earnings (P/E) ratio of Ginkgo Bioworks Holdings (DNA) is NM
The price-to-book (P/B) ratio of Ginkgo Bioworks Holdings (DNA) is 1.98
The dividend yield of Ginkgo Bioworks Holdings (DNA) is 0.00%
The market capitalization of Ginkgo Bioworks Holdings (DNA) is $1.58B
The stock symbol (or ticker) of Ginkgo Bioworks Holdings is DNA
Link copied 
